| GRFT+ |
CI at varying HIV inhibitiona |
Effectb |
| 50% |
75% |
95% |
| Reverse transcriptase inhibitors |
| efavirenz |
0.80 ± 0.28 |
0.48 ± 0.14 |
0.48 ± 0.08 |
+++ |
| tenofovir |
0.63 ± 0.11 |
0.67 ± 0.09 |
0.76 ± 0.06 |
++ |
| UC-781 |
0.51 ± 0.16 |
0.49 ± 0.12 |
0.65 ± 0.06 |
+++ |
| etravirine |
0.91 ± 0.31 |
0.87 ± 0.24 |
1.08 ± 0.12 |
Additivity |
| Integrase inhibitors |
| raltegravir |
0.67 ± 0.17 |
0.59 ± 0.15 |
0.58 ± 0.14 |
+++ |
| elvitegravir |
0.37 ± 0.13 |
0.30 ± 0.14 |
0.64 ± 0.30 |
+++ |
| Protease inhibitor |
| saquinavir |
N.A.a |
N.A.a |
N.A.a |
N.A.a |
aMean CIs ± SEM up to 5 independent experiments are shown. N.A.: not applicable
bEffect of drug interaction based at CI95%, whereby CI<0.9 are synergistic; 0.9<CI<1.1 are additive and CI > 1.1 are antagonistic. The degree of synergy: 0.85<CI<0.9: +
(slight synergy); 0.7<CI<0.85: ++ (moderate synergy); 0.3<CI<0.7: +++ (synergy); 0.1<0.3: ++++ (potent synergy). |
